Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $163 | In Stock | |
5 mg | $448 | In Stock | |
10 mg | $728 | In Stock | |
25 mg | $1,080 | In Stock | |
50 mg | $1,480 | In Stock |
Description | Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma. |
In vitro | Lucatumumab (0.001-10 μg/mL; 4 hours) lysed B-cell chronic lymphocytic leukemia (B-CLL) cells by antibody-dependent cell-mediated cytotoxicity (ADCC) action, achieving a mean maximum lysis rate of 49%. [1] Lucatumumab (0.1-10 μg/mL; 3 days) was able to decrease CD40L-induced signaling and reduce B-CLL cell viability. [1] Lucatumumab (10 μg/mL; 24 hours) is able to inhibit cytokine secretion by B-CLL cells. [1] |
Alias | HCD122, HCD 122, CHIR-12.12 |
Cas No. | 903512-50-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.